Second People's Hospital of Shenzhen Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03515096
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Department of oncology, the second people's hospital of shenzhen | Second People's Hospital of Shenzhen

Active Ingredients

Drugs in Phase 3 Trials (2)

eltrombopag (promacta) (1 trial)

thrombopoietin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2